Philip Sparke is the founder of Replimune Group. Replimune Group has raised $100M in total funding. Latest round: IPO. Backed by Forbion.
Philip Astley-Sparke is the CEO of Replimune Group, a clinical stage biotechnology company focused on developing tumor-directed oncolytic immunotherapies. The company went public on NASDAQ in July 2018, raising over $100 million. Prior to Replimune, he was the President and CEO of BioVex Inc., which was acquired by Amgen in 2011.
Full founder directory · Investor directory · Company funding database · Fundraising library